Anika Therapeutics, Inc. Restructuring Costs and Asset Impairment Charges
Anika Therapeutics, Inc. (ANIK) reported Restructuring Costs and Asset Impairment Charges of -$160.56 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2015-03-13
- Anika Therapeutics, Inc. restructuring costs and asset impairment charges for the quarter ending 2012-12-31 was $2.50M.
- Anika Therapeutics, Inc. restructuring costs and asset impairment charges for fiscal 2013 was -$160.56K, a 110.01% decline from fiscal 2012.
- Anika Therapeutics, Inc. restructuring costs and asset impairment charges for fiscal 2012 was $1.60M.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 12 month |
|---|---|---|---|
| 2013-12-31 | -$160.56K 10-K · filed 2014-03-13 | ||
| 2012-12-31 | $2.50M 10-K · filed 2015-03-13 | $2.50M 10-Q · filed 2013-11-05 | $1.60M 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |